 Cancer Vaccines
"Cancer Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
| Descriptor ID |
D019496
|
| MeSH Number(s) |
D20.215.894.200
|
| Concept/Terms |
Cancer Vaccines- Cancer Vaccines
- Vaccines, Tumor
- Vaccines, Neoplasm
- Tumor Vaccines
- Vaccines, Cancer
- Neoplasm Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Cancer Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Cancer Vaccines".
This graph shows the total number of publications written about "Cancer Vaccines" by people in UAMS Profiles by year, and whether "Cancer Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 2 | 0 | 2 | | 2021 | 3 | 0 | 3 | | 2020 | 3 | 0 | 3 | | 2019 | 4 | 0 | 4 | | 2018 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 | | 2016 | 2 | 0 | 2 | | 2015 | 1 | 0 | 1 | | 2014 | 3 | 2 | 5 | | 2013 | 2 | 0 | 2 | | 2011 | 3 | 4 | 7 | | 2010 | 2 | 0 | 2 | | 2009 | 1 | 0 | 1 | | 2008 | 2 | 0 | 2 | | 2007 | 6 | 1 | 7 | | 2006 | 3 | 0 | 3 | | 2005 | 5 | 0 | 5 | | 2004 | 1 | 0 | 1 | | 2003 | 3 | 0 | 3 | | 2002 | 1 | 0 | 1 | | 2001 | 1 | 2 | 3 | | 1999 | 3 | 0 | 3 | | 1998 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Cancer Vaccines" by people in Profiles over the past ten years.
-
Pashov A, Murali R, Makhoul I, Karbassi B, Kieber-Emmons T. Harnessing Antibody Polyspecificity for Cancer Immunotherapy. Monoclon Antib Immunodiagn Immunother. 2022 Oct; 41(5):290-300.
-
Qazilbash MH, Saini NY, Cha SC, Wang Z, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, Kim K, Popescu M, Szymura S, Zhang T, Anderson A, Bashir Q, Shpall EJ, Orlowski RZ, Levine BL, Kerr N, Garfall A, Cohen A, Vogl DT, Dengel K, June CH, Champlin R, Kwak LW. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Blood. 2022 03 03; 139(9):1289-1301.
-
Thakur S, Jain M, Zhang C, Major C, Bielamowicz KJ, Lacayo NJ, Vaske O, Lewis V, Murguia-Favela L, Narendran A. Identification and in vitro validation of neoantigens for immune activation against high-risk pediatric leukemia cells. Hum Vaccin Immunother. 2021 12 02; 17(12):5558-5562.
-
Shibata T, Shah S, Evans T, Coleman H, Lieblong BJ, Spencer HJ, Quick CM, Sasagawa T, Stephens OW, Peterson E, Johann D, Lu YC, Nakagawa M. Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed. Front Immunol. 2021; 12:645299.
-
Aydin AM, Bunch BL, Beatty M, Hajiran A, Dhillon J, Sarnaik AA, Pilon-Thomas S, Poch MA. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications. Front Immunol. 2021; 12:628063.
-
Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020 10 15; 183(2):347-362.e24.
-
Block MS, Dietz AB, Gustafson MP, Kalli KR, Erskine CL, Youssef B, Vijay GV, Allred JB, Pavelko KD, Strausbauch MA, Lin Y, Grudem ME, Jatoi A, Klampe CM, Wahner-Hendrickson AE, Weroha SJ, Glaser GE, Kumar A, Langstraat CL, Solseth ML, Deeds MC, Knutson KL, Cannon MJ. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. Nat Commun. 2020 10 14; 11(1):5173.
-
Donovan LK, Delaidelli A, Joseph SK, Bielamowicz K, Fousek K, Holgado BL, Manno A, Srikanthan D, Gad AZ, Van Ommeren R, Przelicki D, Richman C, Ramaswamy V, Daniels C, Pallota JG, Douglas T, Joynt ACM, Haapasalo J, Nor C, Vladoiu MC, Kuzan-Fischer CM, Garzia L, Mack SC, Varadharajan S, Baker ML, Hendrikse L, Ly M, Kharas K, Balin P, Wu X, Qin L, Huang N, Stucklin AG, Morrissy AS, Cavalli FMG, Luu B, Suarez R, De Antonellis P, Michealraj A, Rastan A, Hegde M, Komosa M, Sirbu O, Kumar SA, Abdullaev Z, Faria CC, Yip S, Hukin J, Tabori U, Hawkins C, Aldape K, Daugaard M, Maris JM, Sorensen PH, Ahmed N, Taylor MD. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020 05; 26(5):720-731.
-
Ma L, Dichwalkar T, Chang JYH, Cossette B, Garafola D, Zhang AQ, Fichter M, Wang C, Liang S, Silva M, Kumari S, Mehta NK, Abraham W, Thai N, Li N, Wittrup KD, Irvine DJ. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019 07 12; 365(6449):162-168.
-
Shibata T, Lieblong BJ, Sasagawa T, Nakagawa M. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev. 2019 Aug; 78:8-16.
-
Leko V, McDuffie LA, Zheng Z, Gartner JJ, Prickett TD, Apolo AB, Agarwal PK, Rosenberg SA, Lu YC. Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. J Immunol. 2019 06 15; 202(12):3458-3467.
-
Cannon MJ, Block MS, Morehead LC, Knutson KL. The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy. Immunotherapy. 2019 02; 11(2):75-79.
-
Ravindranathan S, Nguyen KG, Kurtz SL, Frazier HN, Smith SG, Koppolu BP, Rajaram N, Zaharoff DA. Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines. Breast Cancer Res. 2018 10 22; 20(1):126.
-
Kieber-Emmons T, Monzavi-Karbassi B, Hutchins LF, Pennisi A, Makhoul I. Harnessing benefit from targeting tumor associated carbohydrate antigens. Hum Vaccin Immunother. 2017 02; 13(2):323-331.
-
Yao X, Lu YC, Parker LL, Li YF, El-Gamil M, Black MA, Xu H, Feldman SA, van der Bruggen P, Rosenberg SA, Robbins PF. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. J Immunother. 2016 06; 39(5):191-201.
-
Lu YC, Robbins PF. Targeting neoantigens for cancer immunotherapy. Int Immunol. 2016 07; 28(7):365-70.
-
Steplewski Z, Thurin M, Kieber-Emmons T. Antibodies: At The Nexus of Antigens and Cancer Vaccines. J Infect Dis. 2015 Jul 15; 212 Suppl 1:S59-66.
-
Makhoul I, Hutchins L, Emanuel PD, Pennisi A, Siegel E, Jousheghany F, Monzavi-Karbassi B, Kieber-Emmons T. Moving a Carbohydrate Mimetic Peptide into the clinic. Hum Vaccin Immunother. 2015; 11(1):37-44.
-
Murali R, Kieber-Emmons T. Cancer immunotherapeutics: evolution of monoclonal antibodies to peptide immunogens. Monoclon Antib Immunodiagn Immunother. 2014 Jun; 33(3):179-82.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|